🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  2. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Advanced Unresectable Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  3. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Thyroid Cancer

    phase 2 small molecule active

    1 trial

  4. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HNSCC

    phase 2 small molecule active

    1 trial

  5. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  6. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    RECTAL NEOPLASMS

    phase 2 small molecule active

    1 trial

  7. Tislelizumab

    BeiGene

    Cervical Cancer

    phase 2 mab completed

    1 trial

  8. Tislelizumab

    Hospital Authority, Hong Kong

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  9. Tislelizumab

    The First People's Hospital of Lianyungang

    HER2-positive or Mutated Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  10. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  11. Tislelizumab

    The First People's Hospital of Lianyungang

    Bladder Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  12. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  13. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  14. Tislelizumab

    Takeda

    Minimal Residual Disease

    phase 2 small molecule active

    1 trial

  15. Tislelizumab

    The First People's Hospital of Lianyungang

    Biliary Tract Tumor

    phase 2 small molecule active

    1 trial

  16. Tislelizumab

    The First People's Hospital of Lianyungang

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  17. Tislelizumab (BGB-A317)

    BEONE MEDICINES AUS PTY LTD

    MSI-H/dMMR Solid Tumors

    phase 2 small molecule active

    1 trial

  18. Tislelizumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    ESCC

    phase 2 small molecule active

    1 trial

  19. Tislelizumab combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  20. Toripalimab

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  21. Toripalimab + Chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Thymic Epithelial Tumor

    phase 2 small molecule active

    1 trial

  22. Trastuzumab deruxtecan

    AstraZeneca

    Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

    phase 2 small molecule active

    1 trial

  23. Tremelimumab placebo, concentrate for solution for infusion, Tremelimumab

    AstraZeneca AB

    unresectable pleural or peritoneal malignant mesothelioma

    phase 2 small molecule active

    1 trial

  24. VGX 3100

    INOVIO PHARMACEUTICALS, INC.

    Cervical Intraepithelial Neoplasia

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources